우리나라의 건강보험 약가 사후관리제도 고찰 및 발전 방안 = An Overview and Suggestions of the Post-listing Control System for Pharmaceutical Pricing in Korea

다국어 초록 (Multilingual Abstract)

This study examines post-listing control systems for pharmaceutical pricing and suggests a reasonable
improvement policy in Korea. There are four post-listing control systems for pharmaceutical pricing in Korean national
health insurance. When each scheme was introduced, they had their own background and goals. But it is very difficult to understand and predict the timing and extent of the price cuts due to complex system by introducing or revising some schemes without clear policy objectives. At the same time, the social costs are often caused by various confusions, including distribution sites, due to frequent price cuts. For this reason, the current post-listing control system needs to be improved. We investigated the latest trends of the post-listing control system of the major countries that operate a similar system through literatures, website, reports of relevant institutions. From a mid- to long-term point of view, the system should be that can enhance the health of the population by comprehensively reflecting drug prescribing behavior and use status under clear target for drug expenditure management. It should also be developed as a system that can create a healthy industrial ecosystem for the development of the pharmaceutical industry.

목차 (Table of Contents)

• 연구방법
• 연구결과
• 고 찰
• 결 론
• 감사의 글
• References

참고문헌 (Reference)

1 국민건강보험공단, "주요국 약제비 관리제도"

2 보건복지부, "제10차 무역투자진흥회의"

3 이종혁, "우리나라 약가 사후관리제도현황 분석 및 합리화방안 연구" 호서대학교 산학협력단/한국다국적의약산업협회 2016

4 "약제의 결정 및 조정기준"

5 일본후생노동성, "약가산정 기준"

6 최은택, "스토가 소송 정리하라는 지적에 정부 “그럴 수 없다”" 데일리팜

7 "사용량-약가 연동 협상 세부운영지침"

8 국민건강보험공단, "국회 제출자료"

9 "국민건강보험 요양급여에 관한 규칙"

10 보건복지부, "건강보험 약제비 적정화 방안" 2006

11 衛生福利部, "國際藥價政策與管理制度讀書會 會議資料"

12 OECD, "Value in pharmaceutical pricing country profile"

13 대만위생복리부, "The National Health Insurance Pharmaceutical Benefits and Reimbursement Schedule"

14 Cornelia, H., "Structural changes in the German pharmaceutical market : Price setting mechanisms based on the early benefit evaluation" 109 : 263-, 2013

15 National Authority for health, "Pricing &Reimbursement of drugs and HTA policies in France"

16 DeSwaef A, "PPRI Pharma Profile Belgium, Pharmaceutical Pricing and Reimbursement Information"

17 IMS health, "IMS Market Prognosis 2014~2018 Europe-France"

18 Medicines australia, "Effects of reforms to the pharmaceutical benefits scheme"